Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

CPNG

Coupang Inc

Nov 10 • 04:00PM ET

28.92

+0.04 0.14 %

Consumer Cyclical • Internet Retail • USA • NYSE

Peers: AMZN BABA JD SHOP EBAY PDD SE ETSY MELI W

| Held by: VXF IWP IWF IWR SCHG VONG ITOT SCHX VT FMDE

Index	-	P/E	136.87	EPS (ttm)	0.21	Insider Own	27.34%	Shs Outstand	1.67B	Perf Week	-9.57%
Market Cap	52.83B	Forward P/E	54.87	EPS next Y	0.53	Insider Trans	-10.78%	Shs Float	1.33B	Perf Month	-7.40%
Enterprise Value	50.45B	PEG	1.07	EPS next Q	0.04	Inst Own	57.96%	Short Float	1.61%	Perf Quarter	2.77%
Income	390.00M	P/S	1.57	EPS this Y	112.15%	Inst Trans	2.05%	Short Ratio	1.91	Perf Half Y	10.64%
Sales	33.66B	P/B	11.12	EPS next Y	210.55%	ROA	2.23%	Short Interest	21.41M	Perf YTD	31.57%
Book/sh	2.60	P/C	7.21	EPS next 5Y	127.65%	ROE	8.73%	52W High	34.08 -15.13%	Perf Year	20.50%
Cash/sh	4.01	P/FCF	42.03	EPS past 3/5Y	- -	ROIC	5.00%	52W Low	19.02 52.05%	Perf 3Y	67.75%
Dividend Est.	-	EV/EBITDA	43.12	Sales past 3/5Y	18.03% 36.99%	Gross Margin	29.62%	Volatility	3.67% 2.47%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.50	EPS Y/Y TTM	-62.54%	Oper. Margin	1.99%	ATR (14)	0.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.82	Sales Y/Y TTM	16.63%	Profit Margin	1.16%	RSI (14)	27.45	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	1.06	EPS Q/Q	33.16%	SMA20	-7.21%	Beta	1.19	Target Price	36.68
Payout	0.00%	Debt/Eq	1.04	Sales Q/Q	17.81%	SMA50	-8.52%	Rel Volume	1.16	Prev Close	28.88
Employees	95000	LT Debt/Eq	0.65	Earnings	Nov 04 AMC	SMA200	5.21%	Avg Volume	11.19M	Price	28.92
IPO	Mar 11, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.61% 1.32%	Trades		Volume	12,933,422	Change	0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	Arete	Buy	$40
Aug-06-25	Upgrade	Nomura	Neutral → Buy	$35
Aug-06-25	Downgrade	Deutsche Bank	Buy → Hold	$27
Feb-26-25	Upgrade	Deutsche Bank	Hold → Buy	$28.50
Oct-07-24	Upgrade	Bernstein	Underperform → Outperform	$30
Sep-04-24	Upgrade	CLSA	Hold → Outperform	$18 → $31
May-16-24	Upgrade	UBS	Neutral → Buy	$26
May-03-24	Resumed	BofA Securities	Buy	$30
Apr-15-24	Upgrade	Citigroup	Neutral → Buy	$19 → $26
Feb-29-24	Upgrade	Deutsche Bank	Hold → Buy	$18.50 → $21
Jan-16-24	Downgrade	Citigroup	Buy → Neutral	$20 → $17
Dec-20-23	Downgrade	UBS	Buy → Neutral	$26 → $18.50
Aug-09-23	Downgrade	Deutsche Bank	Buy → Hold	$20
Mar-02-23	Downgrade	BofA Securities	Buy → Neutral	$27 → $18
Mar-01-23	Upgrade	Deutsche Bank	Hold → Buy	$20
Feb-09-23	Initiated	Barclays	Overweight	$20
Dec-01-22	Initiated	New Street	Buy	$25
Oct-07-22	Initiated	HSBC Securities	Buy	$27.80
Aug-16-22	Downgrade	CLSA	Outperform → Sell	$16.40
Aug-11-22	Downgrade	Deutsche Bank	Buy → Hold	$15 → $18.50

Show Previous Ratings

Nov-09-25 11:43PM	3 Cash-Producing Stocks with Promising Prospects (StockStory)
Nov-05-25 03:46PM	Why Coupang Stock Is Sinking Today (Motley Fool) -5.94%
12:26PM	Why Coupang (CPNG) Shares Are Falling Today (StockStory)
10:42AM	Analyst Report: Coupang, Inc. (Morningstar Research)
08:36AM	CPNG Q3 Deep Dive: Margin Expansion and Taiwan Investment Shape Outlook (StockStory)
12:12AM	Loading…
12:12AM	Coupang Inc (CPNG) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com)
Nov-04-25 08:00PM	Coupang (CPNG) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:30PM	Coupang, Inc. (CPNG) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:25PM	Coupang's (NYSE:CPNG) Q3: Beats On Revenue (StockStory)
04:05PM	Coupang Announces Results for Third Quarter 2025 (Business Wire)
08:36AM	Analyst Report: Coupang, Inc. (Morningstar Research)
Nov-03-25 07:48PM	Coupang Q3 Preview: Can Its Ecosystem Keep Delivering? (GuruFocus.com)
03:23PM	Analyst Explains Why He's Buying This Asian Stock With 'Neat Story' (Insider Monkey)
Nov-02-25 10:09PM	Coupang (CPNG) Reports Earnings Tomorrow: What To Expect (StockStory)
07:40AM	Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week (Yahoo Finance)
01:52PM	Loading…
Oct-31-25 01:52PM	Coupang Set to Report Q3 Earnings: What's in Store for the Stock? (Zacks)
09:00AM	Here is What to Know Beyond Why Coupang, Inc. (CPNG) is a Trending Stock (Zacks)
Oct-30-25 03:30PM	2 Growth Stocks Down 38% and 65% to Buy Right Now (Motley Fool)
Oct-29-25 05:35PM	MercadoLibre (MELI) Misses Q3 Earnings Estimates (Zacks)
Oct-28-25 09:42PM	U.S. Technology Company Coupang Presents Its Vision to Accelerate AI-driven Commerce at the APEC CEO Summit (Business Wire)
Oct-27-25 05:50PM	Coupang, Inc. (CPNG) Rises Higher Than Market: Key Facts (Zacks)
Oct-21-25 10:29PM	Coupang, Inc. (CPNG): A Bull Case Theory (Insider Monkey)
04:05PM	Coupang to Announce Third Quarter 2025 Results on November 4, 2025 (Business Wire)
09:29AM	Coupang Named Official APEC PR Partner, Delivering Messages of Support in South Korea Through Rocket Delivery (Business Wire)
Oct-20-25 06:00PM	Why Coupang, Inc. (CPNG) Outpaced the Stock Market Today (Zacks)
09:00AM	Coupang, Inc. (CPNG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Oct-16-25 05:45AM	3 Risks Investors Should Know Before Buying Coupang Stock (Motley Fool)
Oct-15-25 07:05AM	3 Cheap Growth Stocks You Can Buy for Less Than $100 (Motley Fool)
04:25AM	Coupang Isn't Just Retail. Here's Why Its Tech Bets Matter. (Motley Fool)
Oct-13-25 05:50PM	Coupang, Inc. (CPNG) Outperforms Broader Market: What You Need to Know (Zacks)
01:20PM	Loading…
Oct-12-25 01:20PM	3 Reasons Investors Are Excited About Coupang Stock (Motley Fool)
Oct-10-25 06:00PM	Coupang, Inc. (CPNG) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
01:58PM	Trade Tracker: Kevin Simpson buys Coupang and sells Roblox (CNBC TV)
04:35AM	The Ultimate Growth Stock to Buy With $1,000 Right Now (Motley Fool)
Oct-08-25 05:51PM	Why Coupang Stock Skyrocketed in September (Motley Fool)
Oct-07-25 08:30PM	Is This AI Stock a Better Buy Than Amazon, Nvidia, And Palantir? (Motley Fool)
09:00AM	Coupang, Inc. (CPNG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:00AM	My 3 Favorite Stocks to Buy Right Now (Motley Fool)
03:22AM	Preparing for a Market Crash? Put This AI Technology Stock on Your Watchlist Right Now. (Motley Fool)
Sep-26-25 05:50PM	Coupang, Inc. (CPNG) Outperforms Broader Market: What You Need to Know (Zacks)
12:41AM	2 Surging Stocks with Exciting Potential and 1 We Avoid (StockStory)
Sep-24-25 09:00AM	Investors Heavily Search Coupang, Inc. (CPNG): Here is What You Need to Know (Zacks)
09:00AM	Coupang Powers Lemme's Expansion Into South Korea, Bringing U.S. Wellness Brand to Millions of New Customers (Business Wire)
Sep-22-25 10:09AM	Fiverr (FVRR) Soars 5.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-19-25 05:50PM	Coupang, Inc. (CPNG) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Sep-18-25 06:38PM	SoftBank Vision Fund to lay off 20% of employees in shift to bold AI bets, source and memo say (Reuters)
08:19AM	4 Stocks to Buy on a Pullback (Motley Fool)
Sep-16-25 03:45AM	Not Nearly Enough Investors Are Talking About Coupang Stock (Motley Fool)
Sep-12-25 09:30AM	Is It Worth Investing in Coupang (CPNG) Based on Wall Street's Bullish Views? (Zacks)
08:30AM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
12:39AM	1 Unpopular Stock That Deserves a Second Chance and 2 That Underwhelm (StockStory)
Sep-11-25 05:50PM	Why Coupang, Inc. (CPNG) Outpaced the Stock Market Today (Zacks)
04:00PM	Is Coupang the Next MercadoLibre? A Playbook for Global Dominance (MarketBeat)
07:00AM	This Under-the-Radar Technology Stock Is Now a Home-Run AI Investment (Motley Fool)
Sep-10-25 02:23PM	E-commerce giant Coupang wins dismissal of US shareholder lawsuit over IPO (Reuters)
09:00AM	Here is What to Know Beyond Why Coupang, Inc. (CPNG) is a Trending Stock (Zacks)
04:25AM	Is Coupang Stock a Can't-Miss Opportunity Below $30? (Motley Fool)
Sep-09-25 03:01PM	Coupang Stock Sees Relative Strength Rating Jump To 86 (Investor's Business Daily)
10:58AM	Coupang (CPNG) Hits Fresh High After Scoring Washington Capitals Deal (Insider Monkey)
Sep-08-25 06:55PM	Analyst Report: Coupang, Inc. (Morningstar Research) +8.96%
02:25PM	Coupang (CPNG) Stock Trades Up, Here Is Why (StockStory)
Sep-07-25 03:15AM	2 Stocks That Could Be Easy Wealth Builders (Motley Fool)
Sep-03-25 08:03AM	Washington Capitals Announce Coupang as Home and Third Jersey Patch Partner (PR Newswire)
Aug-29-25 05:24AM	Morgan Stanley Raises PT on Coupang, Inc. (CPNG) to $35; Maintains 'Overweight' Rating (Insider Monkey)
12:35AM	3 Large-Cap Stocks with Solid Fundamentals (StockStory)
Aug-27-25 12:03AM	Coupang (CPNG): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Aug-26-25 04:18AM	Coupang, Inc. (CPNG): A Bull Case Theory (Insider Monkey)
Aug-25-25 09:00AM	Is Trending Stock Coupang, Inc. (CPNG) a Buy Now? (Zacks)
Aug-24-25 06:45AM	Should You Forget Palantir and Buy These 2 Millionaire-Maker Stocks Instead? (Motley Fool)
Aug-22-25 09:30AM	Is Coupang (CPNG) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Aug-18-25 11:35PM	Q2 Earnings Roundup: Coupang (NYSE:CPNG) And The Rest Of The Online Retail Segment (StockStory)
Aug-17-25 10:30AM	2 Tech Stocks With More Potential Than Any Cryptocurrency (Motley Fool)
Aug-12-25 11:17PM	5 Revealing Analyst Questions From Coupang's Q2 Earnings Call (StockStory)
11:07PM	CPNG Q2 2025 Deep Dive: Margin Expansion and Investment in Emerging Markets Shape Outlook (StockStory)
09:58AM	1 of Wall Street's Favorite Stock with Solid Fundamentals and 2 We Avoid (StockStory)
09:00AM	Coupang, Inc. (CPNG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Aug-07-25 09:18PM	SoftBank Shares Surge to Record on AI-Fueled Profit Recovery (Bloomberg)
10:32AM	Nvidia, AI Bets Lift SoftBank To Profit After Brutal Year-Ago Loss (Benzinga)
Aug-06-25 10:37AM	Analyst Report: Coupang, Inc. (Morningstar Research) -6.05%
03:36AM	Coupang Inc (CPNG) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion (GuruFocus.com)
Aug-05-25 08:51PM	Coupang Slides on Q2 Profit and Cash-Flow Miss (GuruFocus.com)
06:16PM	Coupang (NYSE:CPNG) Exceeds Q2 Expectations (StockStory)
06:00PM	Coupang, Inc. (CPNG) Q2 Earnings Miss Estimates (Zacks)
04:05PM	Coupang Announces Results for Second Quarter 2025 (Business Wire)
10:45AM	MercadoLibre Q2 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
Aug-04-25 08:41AM	Coupang Q2 Preview: Growth Strong, Expectations Higher (GuruFocus.com)
08:10AM	Wayfair (W) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-03-25 11:06PM	Coupang (CPNG) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Aug-01-25 12:28PM	Coupang Set to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
12:00PM	Coupang (CPNG) Upgraded to Buy: Here's What You Should Know (Zacks)
Jul-31-25 09:30AM	Brokers Suggest Investing in Coupang (CPNG): Read This Before Placing a Bet (Zacks)
Jul-30-25 05:50PM	Coupang, Inc. (CPNG) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Jul-28-25 09:40AM	Are Retail-Wholesale Stocks Lagging Coupang (CPNG) This Year? (Zacks)
09:00AM	Coupang Keeps Hitting New Highs. Should You Buy CPNG Stock in July 2025? (Barchart)
Jul-24-25 06:00PM	Coupang, Inc. (CPNG) Stock Dips While Market Gains: Key Facts (Zacks)
Jul-22-25 04:05PM	Coupang to Announce Second Quarter 2025 Results on August 5, 2025 (Business Wire)
09:00AM	Coupang, Inc. (CPNG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jul-18-25 05:50PM	Why the Market Dipped But Coupang, Inc. (CPNG) Gained Today (Zacks)
05:45PM	Prediction: 2 Stocks That Will Be Worth More Than CoreWeave 10 Years From Now (Motley Fool)
12:02AM	2 Reasons to Watch CPNG and 1 to Stay Cautious (StockStory)

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GAURAV ANAND	Officer	Nov 10 '25	Proposed Sale	28.88	75,350	2,176,108		Nov 10 04:34 PM
Kolari Pranam	VP, Search and Recommendations	Nov 03 '25	Sale	31.98	11,653	372,608	147,023	Nov 05 04:24 PM
Pranam Kolari	Officer	Nov 03 '25	Proposed Sale	31.98	11,653	372,608		Nov 03 04:15 PM
Franceschi Pedro	Director	Sep 11 '25	Sale	32.05	21,428	686,767	0	Sep 12 04:21 PM
Rogers Harold	See Remarks	Sep 11 '25	Sale	32.06	64,755	2,075,793	449,569	Sep 12 04:20 PM
Pedro Franceschi	Director	Sep 11 '25	Proposed Sale	32.12	21,428	688,267		Sep 11 05:17 PM
Harold Rogers	Affiliate	Sep 11 '25	Proposed Sale	32.06	64,755	2,075,795		Sep 11 04:16 PM
Sun Benjamin	Director	Sep 09 '25	Sale	31.88	815,797	26,007,626	503,624	Sep 10 04:49 PM
Benjamin Sun	Affiliate	Sep 09 '25	Proposed Sale	31.88	815,797	26,007,404		Sep 09 04:47 PM
Han Seung Kang	affiliate	Aug 28 '25	Proposed Sale	28.24	25,000	706,000		Aug 28 04:07 PM
SVF Investments (UK) Ltd	10% Owner	Aug 20 '25	Sale	28.00	20,000,000	560,000,000	289,542,259	Aug 22 09:00 PM
SVF Investments (UK) Ltd	Shareholder	Aug 20 '25	Proposed Sale	28.84	20,000,000	576,800,000		Aug 20 09:00 PM
Anand Gaurav	Chief Financial Officer	Aug 11 '25	Sale	27.79	75,350	2,093,803	2,016,940	Aug 12 04:34 PM
GAURAV ANAND	Officer	Aug 11 '25	Proposed Sale	27.83	75,350	2,096,990		Aug 11 04:22 PM
Kolari Pranam	VP, Search and Recommendations	Aug 04 '25	Sale	29.14	11,653	339,568	158,676	Aug 04 04:41 PM
Pranam Kolari	affiliate	Aug 04 '25	Proposed Sale	29.14	11,653	339,568		Aug 04 04:24 PM
SVF Investments (UK) Ltd	10% Owner	Jun 13 '25	Sale	28.25	10,000,000	282,500,000	309,542,259	Jun 17 09:00 PM
SVF Investments (UK) Ltd	Shareholder	Jun 13 '25	Proposed Sale	28.31	10,000,000	283,100,000		Jun 13 09:00 PM
Anand Gaurav	Chief Financial Officer	May 29 '25	Sale	28.11	175,000	4,919,635	2,092,290	Jun 02 04:21 PM
Sun Benjamin	Director	May 28 '25	Sale	28.36	200,000	5,671,560	1,319,421	May 30 04:39 PM
Gaurav Anand	affiliate	May 29 '25	Proposed Sale	28.11	175,000	4,919,627		May 29 06:12 PM
Benjamin Sun	Affiliate	May 28 '25	Proposed Sale	28.33	200,000	5,665,552		May 28 04:30 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 14 '25	Buy	26.78	750,000	20,082,300	54,481,161	May 16 07:30 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	May 15 '25	Buy	26.86	650,000	17,458,610	55,131,161	May 16 07:30 PM
Anand Gaurav	Chief Financial Officer	May 12 '25	Sale	26.10	75,350	1,966,921	2,267,290	May 14 04:21 PM
SVF Investments (UK) Ltd	10% Owner	May 08 '25	Sale	25.75	30,000,000	772,500,000	319,542,259	May 12 09:00 PM
GAURAV ANAND	Officer	May 12 '25	Proposed Sale	26.00	75,350	1,959,100		May 12 04:23 PM
Sun Benjamin	Director	May 08 '25	Sale	26.03	200,000	5,206,120	1,519,421	May 12 04:15 PM
Kang Hanseung	Rep Director, Business Mngmt	May 08 '25	Sale	26.17	69,931	1,830,248	599,841	May 12 04:14 PM
Lee Jonathan D.	Chief Accounting Officer	May 08 '25	Sale	26.17	8,105	212,126	124,775	May 12 04:12 PM
Kolari Pranam	VP, Search and Recommendations	May 08 '25	Sale	26.17	6,777	177,385	170,329	May 12 04:10 PM
SVF Investments (UK) Ltd	Shareholder	May 08 '25	Proposed Sale	26.60	30,000,000	798,000,000		May 08 09:00 PM
Pranam Kolari	affiliate	May 08 '25	Proposed Sale	26.17	6,777	177,385		May 08 04:35 PM
Benjamin Sun	Affiliate	May 08 '25	Proposed Sale	26.00	200,000	5,199,322		May 08 04:29 PM
Han Seung Kang	affiliate	May 08 '25	Proposed Sale	26.17	69,931	1,830,247		May 08 04:29 PM
Jonathan Lee	affiliate	May 08 '25	Proposed Sale	26.17	8,105	212,127		May 08 04:22 PM
Kolari Pranam	VP, Search and Recommendations	May 02 '25	Sale	23.85	9,347	222,926	177,106	May 02 09:16 PM
Pranam Kolari	affiliate	May 02 '25	Proposed Sale	23.47	9,347	219,374		May 02 08:34 PM
Kolari Pranam	VP, Search and Recommendations	Apr 02 '25	Sale	21.94	675	14,810	186,453	Apr 03 04:24 PM
Pranam Kolari	affiliate	Apr 02 '25	Proposed Sale	22.18	675	14,972		Apr 02 06:52 PM
Sun Benjamin	Director	Mar 17 '25	Sale	23.43	250,000	5,856,853	1,719,421	Mar 19 09:06 PM
Kang Hanseung	Rep Director, Business Mngmt	Mar 17 '25	Sale	23.00	40,000	920,000	669,772	Mar 19 04:23 PM
Han Seung Kang	affiliate	Mar 17 '25	Proposed Sale	22.51	40,000	900,400		Mar 17 05:01 PM
Benjamin Sun	Affiliate	Mar 17 '25	Proposed Sale	23.40	250,000	5,849,185		Mar 17 04:39 PM
Anand Gaurav	Chief Financial Officer	Mar 10 '25	Sale	22.03	75,350	1,660,262	2,342,640	Mar 11 04:27 PM
GAURAV ANAND	Officer	Mar 10 '25	Proposed Sale	22.75	75,350	1,714,212		Mar 10 04:24 PM
Rogers Harold	See Remarks	Mar 05 '25	Sale	23.50	273,977	6,437,473	514,324	Mar 07 04:24 PM
Harold Rogers	affiliate	Mar 05 '25	Proposed Sale	23.36	273,977	6,400,103		Mar 05 04:36 PM
Kolari Pranam	VP, Search and Recommendations	Feb 27 '25	Sale	24.76	7,172	177,579	129,634	Feb 28 04:22 PM
Pranam Kolari	affiliate	Feb 27 '25	Proposed Sale	25.01	7,172	179,372		Feb 27 04:28 PM
Kolari Pranam	VP, Search and Recommendations	Feb 03 '25	Sale	22.98	8,459	194,388	136,806	Feb 04 04:23 PM
Pranam Kolari	affiliate	Feb 03 '25	Proposed Sale	23.51	8,459	198,871		Feb 03 04:22 PM
Kolari Pranam	VP, Search and Recommendations	Jan 02 '25	Sale	22.10	775	17,128	145,265	Jan 02 08:33 PM
Pranam Kolari	affiliate	Jan 02 '25	Proposed Sale	21.98	775	17,035		Jan 02 07:20 PM
GREENOAKS CAPITAL PARTNERS LLC	Director	Nov 12 '24	Buy	24.46	200,000	4,891,940	52,926,423	Nov 12 09:15 PM

Open in Screener

ROIV

Roivant Sciences Ltd

Nov 10 • 04:00PM ET

21.17

+0.55 2.67 %

Healthcare • Biotechnology • United Kingdom • NASD

ROIV Roivant Sciences Ltd daily Stock Chart

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB XBI VBK VXF MDY IBB IJK SPMD

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	39.18%	Shs Outstand	689.70M	Perf Week	8.01%
Market Cap	14.46B	Forward P/E	-	EPS next Y	-1.40	Insider Trans	-3.12%	Shs Float	415.35M	Perf Month	31.98%
Enterprise Value	10.61B	PEG	-	EPS next Q	-0.32	Inst Own	64.03%	Short Float	6.08%	Perf Quarter	82.97%
Income	-373.97M	P/S	711.10	EPS this Y	-416.83%	Inst Trans	-5.57%	Short Ratio	3.18	Perf Half Y	92.63%
Sales	20.33M	P/B	3.35	EPS next Y	-12.78%	ROA	-12.44%	Short Interest	25.27M	Perf YTD	78.95%
Book/sh	6.32	P/C	3.29	EPS next 5Y	-	ROE	-14.73%	52W High	20.77 1.93%	Perf Year	80.17%
Cash/sh	6.43	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-8.40%	52W Low	8.73 142.50%	Perf 3Y	289.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	70.12%	Volatility	4.34% 3.52%	Perf 5Y	-
Dividend TTM	-	EV/Sales	521.91	EPS Y/Y TTM	-109.22%	Oper. Margin	-5659.41%	ATR (14)	0.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	33.70	Sales Y/Y TTM	-83.82%	Profit Margin	-1839.58%	RSI (14)	85.51	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	33.70	EPS Q/Q	46.74%	SMA20	12.82%	Beta	1.22	Target Price	21.80
Payout	-	Debt/Eq	0.02	Sales Q/Q	-64.89%	SMA50	29.50%	Rel Volume	1.57	Prev Close	20.62
Employees	750	LT Debt/Eq	0.02	Earnings	Nov 10 BMO	SMA200	71.76%	Avg Volume	7.93M	Price	21.17
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.87% -72.04%	Trades		Volume	12,418,954	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Loading…
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Loading…
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)
Jan-29-25 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 (GlobeNewswire)
Jan-15-25 08:49PM	Vivek Ramaswamy Open to Replacing JD Vance in Senateif Offered (The Wall Street Journal)
Jan-12-25 09:40AM	Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 03:28AM	Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing (Insider Monkey)
Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-16-24 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 (GlobeNewswire)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
May-07-24 02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
May-01-24 10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-25-24 08:00AM	Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis (Business Wire)
Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Sale	16.15	355,161	5,735,850	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Sale	16.34	171,396	2,800,611	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Sale	16.20	138,602	2,245,352	1,504,959	Oct 08 09:00 PM
Venker Eric	Officer	Oct 08 '25	Proposed Sale	16.20	138,602	2,244,797		Oct 08 04:15 PM
Venker Eric	Officer	Oct 07 '25	Proposed Sale	16.15	355,161	5,734,289		Oct 07 04:34 PM
Venker Eric	Officer	Oct 06 '25	Proposed Sale	16.34	171,396	2,800,365		Oct 06 04:46 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Option Exercise	3.85	1,000,000	3,850,000	2,653,585	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Option Exercise	3.85	562,374	2,165,140	2,532,141	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Sale	14.95	683,818	10,223,079	1,969,767	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 23 '25	Sale	14.83	611,000	9,061,130	1,504,959	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Sale	14.99	416,182	6,240,568	2,115,959	Sep 23 09:00 PM
Venker Eric	Officer	Sep 23 '25	Proposed Sale	14.94	611,079	9,129,520		Sep 23 09:45 AM
ERIC VENKER	Officer	Sep 22 '25	Proposed Sale	14.99	316,182	4,741,054		Sep 22 04:20 PM
Venker Eric	Officer	Sep 22 '25	Proposed Sale	15.01	100,000	1,501,339		Sep 22 04:07 PM
ERIC VENKER	Officer	Sep 19 '25	Proposed Sale	14.95	683,818	10,220,412		Sep 19 04:32 PM
Gline Matthew	CEO	Sep 18 '25	Buy	15.07	3,315	49,957	17,287,081	Sep 18 07:28 PM
Ramaswamy Vivek	10% Owner	Sep 03 '25	Sale	12.50	1,195,000	14,937,500	36,089,108	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 05 '25	Sale	12.96	385,816	5,000,175	35,508,359	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 04 '25	Sale	12.92	194,933	2,518,534	35,894,175	Sep 05 05:01 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Option Exercise	3.85	100,000	385,000	1,753,585	Aug 22 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Sale	11.72	100,000	1,172,000	1,653,585	Aug 22 09:00 PM
Venker Eric	Officer	Aug 20 '25	Proposed Sale	11.72	100,000	1,172,120		Aug 20 04:30 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jul 23 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Sale	11.52	100,000	1,152,000	1,462,223	Jul 23 09:00 PM
Venker Eric	Officer	Jul 21 '25	Proposed Sale	11.52	100,000	1,151,942		Jul 21 04:34 PM
Venker Eric	President & COO	Jun 20 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jun 24 09:01 PM
Venker Eric	President & COO	Jun 20 '25	Sale	11.45	100,000	1,145,000	1,462,223	Jun 24 09:01 PM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Sale	11.46	577,007	6,612,500	37,284,108	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Sale	11.45	565,266	6,472,296	37,861,115	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Proposed Sale	11.46	577,007	6,611,850		Jun 20 04:35 PM
Venker Eric	Officer	Jun 20 '25	Proposed Sale	11.45	100,000	1,145,268		Jun 20 04:13 PM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Proposed Sale	11.45	565,266	6,472,996		Jun 18 04:38 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Sale	11.34	547,430	6,207,856	38,627,181	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Sale	11.19	200,800	2,246,952	38,426,381	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Proposed Sale	11.19	200,800	2,246,311		Jun 06 04:33 PM
Venker Eric	President & COO	Jun 03 '25	Option Exercise	3.85	785,026	3,022,350	2,028,501	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Option Exercise	3.85	600,000	2,310,000	1,677,197	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 03 '25	Sale	11.22	566,278	6,353,639	1,462,223	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Sale	11.07	433,722	4,801,303	1,243,475	Jun 04 09:00 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Proposed Sale	11.34	547,430	6,208,008		Jun 04 04:42 PM
ERIC VENKER	Officer	Jun 03 '25	Proposed Sale	11.22	566,278	6,355,961		Jun 03 05:14 PM
ERIC VENKER	Officer	Jun 02 '25	Proposed Sale	11.07	433,722	4,803,341		Jun 02 04:16 PM
Venker Eric	President & COO	May 20 '25	Option Exercise	3.85	100,000	385,000	1,177,197	May 22 09:00 PM
Venker Eric	President & COO	May 20 '25	Sale	10.95	100,000	1,095,000	1,077,197	May 22 09:00 PM
Venker Eric	Officer	May 20 '25	Proposed Sale	10.95	100,000	1,094,986		May 20 04:30 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Sale	11.18	625,000	6,987,500	39,174,611	May 08 08:51 PM
Ramaswamy Vivek	10% Owner	May 06 '25	Sale	11.47	273,959	3,142,310	39,799,611	May 08 08:51 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Proposed Sale	11.18	625,000	6,987,388		May 07 04:37 PM
Ramaswamy Vivek	10% Owner	May 06 '25	Proposed Sale	11.47	273,959	3,143,287		May 06 04:21 PM
Venker Eric	President & COO	Apr 21 '25	Option Exercise	3.85	100,000	385,000	1,216,345	Apr 22 09:00 PM
Venker Eric	President & COO	Apr 21 '25	Sale	10.22	100,000	1,022,000	1,116,345	Apr 22 09:00 PM
Venker Eric	Officer	Apr 21 '25	Proposed Sale	10.22	100,000	1,022,374		Apr 21 03:22 PM
Venker Eric	President & COO	Mar 24 '25	Option Exercise	3.85	602,311	2,318,897	1,561,768	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 20 '25	Option Exercise	3.85	400,000	1,540,000	1,274,979	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 24 '25	Sale	10.82	434,478	4,701,052	1,127,290	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 20 '25	Sale	11.06	315,522	3,489,673	959,457	Mar 24 09:21 PM
Venker Eric	Officer	Mar 20 '25	Proposed Sale	10.95	650,000	7,117,500		Mar 20 05:27 PM
Venker Eric	Officer	Mar 20 '25	Proposed Sale	11.11	100,000	1,110,537		Mar 20 03:54 PM
Venker Eric	President & COO	Feb 20 '25	Option Exercise	3.85	100,000	385,000	996,869	Feb 24 09:00 PM
Venker Eric	President & COO	Feb 20 '25	Sale	10.65	100,000	1,065,000	896,869	Feb 24 09:00 PM
Venker Eric	Officer	Feb 20 '25	Proposed Sale	10.65	100,000	1,065,022		Feb 20 03:35 PM
Kumar Rakhi	Chief Accounting Officer	Feb 13 '25	Option Exercise	3.85	187,500	721,875	390,764	Feb 18 09:00 PM
Kumar Rakhi	Chief Accounting Officer	Feb 13 '25	Sale	10.43	227,500	2,372,825	163,264	Feb 18 09:00 PM
Venker Eric	President & COO	Feb 12 '25	Option Exercise	3.85	300,000	1,155,000	1,032,294	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 13 '25	Option Exercise	3.85	300,000	1,155,000	1,114,910	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 12 '25	Sale	10.53	217,384	2,289,054	732,294	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 13 '25	Sale	10.42	218,041	2,271,987	896,869	Feb 14 09:00 PM
Kumar Rakhi	Officer	Feb 13 '25	Proposed Sale	10.43	227,500	2,372,966		Feb 13 05:14 PM
Venker Eric	Officer	Feb 12 '25	Proposed Sale	10.50	600,000	6,300,000		Feb 12 05:29 PM
Venker Eric	President & COO	Jan 21 '25	Option Exercise	3.85	100,000	385,000	832,294	Jan 22 09:04 PM
Venker Eric	President & COO	Jan 21 '25	Sale	11.28	100,000	1,128,000	732,294	Jan 22 09:04 PM
Venker Eric	Officer	Jan 21 '25	Proposed Sale	11.28	100,000	1,128,457		Jan 21 04:30 PM
Roivant Sciences Ltd.	Director	Jan 13 '25	Buy	20.00	16,845,010	336,900,200	96,650,341	Jan 15 04:36 PM
Venker Eric	President & COO	Dec 27 '24	Option Exercise	3.85	250,000	962,500	845,580	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 30 '24	Option Exercise	3.85	250,000	962,500	918,680	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 27 '24	Sale	11.82	176,900	2,090,958	668,680	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 30 '24	Sale	11.54	177,704	2,050,704	740,976	Dec 31 09:00 PM
Venker Eric	Officer	Dec 27 '24	Proposed Sale	11.75	360,000	4,230,000		Dec 27 04:54 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 26 '24	Option Exercise	3.85	689,495	2,654,556	19,526,042	Dec 26 09:00 PM

CPNG

Coupang Inc

ROIV

Roivant Sciences Ltd

Upgrade your FINVIZ experience